135 related articles for article (PubMed ID: 21906698)
41. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus.
Szécsi J; Gabriel G; Edfeldt G; Michelet M; Klenk HD; Cosset FL
J Infect Dis; 2009 Jul; 200(2):181-90. PubMed ID: 19505256
[TBL] [Abstract][Full Text] [Related]
42. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
[TBL] [Abstract][Full Text] [Related]
43. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
44. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
45. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.
Simmons CP; Bernasconi NL; Suguitan AL; Mills K; Ward JM; Chau NV; Hien TT; Sallusto F; Ha do Q; Farrar J; de Jong MD; Lanzavecchia A; Subbarao K
PLoS Med; 2007 May; 4(5):e178. PubMed ID: 17535101
[TBL] [Abstract][Full Text] [Related]
46. Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains.
Ikeno D; Kimachi K; Ibaragi K; Kudo Y; Goto S; Odoh K; Itamura S; Odagiri T; Tashiro M; Kino Y
Vaccine; 2011 May; 29(24):4156-61. PubMed ID: 21497637
[TBL] [Abstract][Full Text] [Related]
47. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.
Murakami S; Iwasa A; Iwatsuki-Horimoto K; Ito M; Kiso M; Kida H; Takada A; Nidom CA; Mai le Q; Yamada S; Imai H; Sakai-Tagawa Y; Kawaoka Y; Horimoto T
Vaccine; 2008 Nov; 26(50):6398-404. PubMed ID: 18804131
[TBL] [Abstract][Full Text] [Related]
48. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine.
Stittelaar KJ; Lacombe V; van Lavieren R; van Amerongen G; Simon J; Cozette V; Swayne DE; Poulet H; Osterhaus AD
Vaccine; 2010 Jul; 28(31):4970-6. PubMed ID: 20566392
[TBL] [Abstract][Full Text] [Related]
49. Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.
Ichinohe T; Nagata N; Strong P; Tamura S; Takahashi H; Ninomiya A; Imai M; Odagiri T; Tashiro M; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2007 Jun; 79(6):811-9. PubMed ID: 17457919
[TBL] [Abstract][Full Text] [Related]
50. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.
Garg S; Hoelscher M; Belser JA; Wang C; Jayashankar L; Guo Z; Durland RH; Katz JM; Sambhara S
Clin Vaccine Immunol; 2007 Jul; 14(7):926-8. PubMed ID: 17494637
[TBL] [Abstract][Full Text] [Related]
51. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
[TBL] [Abstract][Full Text] [Related]
52. New method to produce equine antirabies immunoglobulin F(ab')₂ fragments from crude plasma in high quality and yield.
Kittipongwarakarn S; Hawe A; Tantipolphan R; Limsuwun K; Khomvilai S; Puttipipatkhachorn S; Jiskoot W
Eur J Pharm Biopharm; 2011 Jun; 78(2):189-95. PubMed ID: 21414404
[TBL] [Abstract][Full Text] [Related]
53. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
[TBL] [Abstract][Full Text] [Related]
54. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.
Itoh Y; Yoshida R; Shichinohe S; Higuchi M; Ishigaki H; Nakayama M; Pham VL; Ishida H; Kitano M; Arikata M; Kitagawa N; Mitsuishi Y; Ogasawara K; Tsuchiya H; Hiono T; Okamatsu M; Sakoda Y; Kida H; Ito M; Quynh Mai L; Kawaoka Y; Miyamoto H; Ishijima M; Igarashi M; Suzuki Y; Takada A
PLoS Pathog; 2014 Jun; 10(6):e1004192. PubMed ID: 24945244
[TBL] [Abstract][Full Text] [Related]
55. Equine immunoglobulin F(ab')
Cui Z; Li D; Yi S; Guo Y; Dong G; Niu J; Zhao H; Zhang Y; Zhang S; Cao L; Wang K; Zhao Y; Hu G
Int Immunopharmacol; 2019 Oct; 75():105714. PubMed ID: 31352323
[TBL] [Abstract][Full Text] [Related]
56. Development of neutralization antibodies against highly pathogenic H5N1 avian influenza virus using ostrich (Struthio camelus) yolk.
Adachi K; Handharyani E; Sari DK; Takama K; Fukuda K; Endo I; Yamamoto R; Sawa M; Tanaka M; Konishi I; Tsukamoto Y
Mol Med Rep; 2008; 1(2):203-9. PubMed ID: 21479398
[TBL] [Abstract][Full Text] [Related]
57. Equine Immunoglobulin and Equine Neutralizing F(ab')₂ Protect Mice from West Nile Virus Infection.
Cui J; Zhao Y; Wang H; Qiu B; Cao Z; Li Q; Zhang Y; Yan F; Jin H; Wang T; Sun W; Feng N; Gao Y; Sun J; Wang Y; Perlman S; Zhao J; Yang S; Xia X
Viruses; 2016 Dec; 8(12):. PubMed ID: 27999340
[TBL] [Abstract][Full Text] [Related]
58. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic Efficacy of Equine Immunoglobulin F(ab')
Liu J; Zhang Z; Bai A; Sha Y; Ma L; Qin S; Chen F; Qin S; Wu J
Appl Biochem Biotechnol; 2021 Oct; 193(10):3151-3162. PubMed ID: 34086256
[TBL] [Abstract][Full Text] [Related]
60. Equine immunoglobulin F(ab')
Zhao Y; Zheng X; He S; Li Y; Wang W; Gai W; Wong G; Wang H; Yan F; Xue F; Feng N; Wang T; Gao Y; Yang S; Qiu X; Xia X
Int Immunopharmacol; 2018 Nov; 64():217-222. PubMed ID: 30199846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
